Very Solid small company,The Group's financial report for the year ended 30 June 2018 includes:
• Operating revenue from services continued its upward trend reaching $1,176,457, a 27% increase compared tothe previous year.
• Combined income from all sources rose 16% to $2.15 million. Revenue from ordinary activities encapsulatesincome from the Company's analytical services, licensing fees, and grant income including the R&D TaxIncentive.
• Operational expenditure totalled $3.59 million, an increase of 29% in-line with budget, and reflecting anincrease in activity in the commercialisation of PromarkerD and the launch of new analytical services.
• The loss from ordinary activities is $1.44million, which represents a year on year increase of 57%.
• At 30 June 2018 the Company had cash reserves of $2.5 million. On the back of the Company's research anddevelopment focus it anticipates an R&D Tax Incentive cash rebate of $844,123, to be received in the Decemberquarter.
- Forums
- ASX - By Stock
- Ann: Annual Report to shareholders
PIQ
proteomics international laboratories ltd
Add to My Watchlist
3.45%
!
30.0¢

Very Solid small company,The Group's financial report for the...
Featured News
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
|
|||||
Last
30.0¢ |
Change
0.010(3.45%) |
Mkt cap ! $49.05M |
Open | High | Low | Value | Volume |
30.5¢ | 30.5¢ | 29.0¢ | $48.86K | 162.9K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
2 | 9700 | 30.0¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
30.5¢ | 5000 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 1000 | 0.300 |
3 | 56779 | 0.295 |
4 | 23542 | 0.290 |
1 | 10000 | 0.285 |
4 | 40643 | 0.280 |
Price($) | Vol. | No. |
---|---|---|
0.305 | 5000 | 1 |
0.310 | 1712 | 2 |
0.315 | 712 | 1 |
0.330 | 30149 | 2 |
0.345 | 1260 | 1 |
Last trade - 10.42am 27/06/2025 (20 minute delay) ? |
Featured News
PIQ (ASX) Chart |
The Watchlist
PTX
PRESCIENT THERAPEUTICS LIMITED
James McDonnell, CEO
James McDonnell
CEO
Previous Video
Next Video
SPONSORED BY The Market Online